Quote this publication Share Print

KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Jul 19 2018

Reason for request

Inclusion

High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:

  • failure of at least two treatments including non-biological systemic treatments and light therapy

  • and an extensive form and/or significant psychosocial impact

but no proven clinical added value compared to COSENTYX and TALTZ.

 

Insufficient clinical benefit to justify reimbursement for other forms.

 

  •  KYNTHEUM is an IL17 receptor A inhibitor that has been granted a marketing authorisation for moderate to severe plaque psoriasis in adults requiring systemic treatment.
  • Similar to the other IL17 antagonists, COSENTYX and TALTZ, it has demonstrated its superiority over STELARA.

  • KYNTHEUM is a systemic treatment to be reserved for the treatment of plaque psoriasis in adults, for patients with severe, chronic plaque psoriasis, defined by:

 

  • failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy

  • and an extensive form and/or significant psychosocial impact.

 

 


Clinical Benefit

Substantial

-

Insufficient

Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments